Novavax (NVAX) had fallen behind in the race to get a Covid-19 vaccine to market and watched as others gained approval and made successful market entries with their respective offerings. However, last week Novavax finally released the data for its U.S./Mexico late-stage trials and the results were excellent, placing the biotech in the same league as its rivals. The trial’s success is the third such study Novavax’s Covid-19 vaccine candidate NVX-CoV2373 has excelled at following successful tests in the U.K. and South Africa.
In this article
No tags related to this article.